Summary of aTyr Pharma Conference Call Company Overview - **Company**: aTyr Pharma - **Focus**: Development of therapies targeting inflammation and fibrosis through tRNA synthetase biology [1][2] Core Points and Arguments Pipeline and Lead Therapy - **Lead Therapy**: Efzofitimod, which has completed a Phase 3 trial and is scheduled for a US FDA Type C meeting in mid-April [2][3] - **Pipeline**: Includes ATYR0101, targeting myofibroblasts for fibrosis, expected to enter the clinic next year [3] Target Conditions - **Primary Focus**: Interstitial lung disease (ILD), particularly sarcoidosis and scleroderma-related ILDs [4][5] - **Market Potential**: ILD market estimated at up to $5 billion, with current therapies being toxic and not disease-modifying [5] Mechanism of Action - **Efzofitimod**: Targets innate immunity at inflammation sites, down-regulating pro-inflammatory signals through interaction with macrophages and Neuropilin-2 receptor [6][8] - **Treatment Approach**: Aims to be a steroid-sparing agent, reducing reliance on steroids which are currently the legacy treatment [11][26] Clinical Trial Results - **Phase III Trial**: Enrolled 268 patients across multiple countries, testing different dosages of efzofitimod [12] - **Steroid Reduction**: Nearly 80% reduction in steroid use observed, although the primary endpoint was not statistically significant [16][18] - **Quality of Life Improvements**: Significant improvements in patient-reported outcomes, particularly in lung symptoms and overall health [19][21] Safety and Tolerability - **Safety Profile**: Efzofitimod well-tolerated with low rates of serious adverse events [25][26] - **Antibody Response**: No concerning treatment-boosted anti-drug antibodies observed [26] Future Directions - **FDA Meeting**: Anticipated discussions on the viability of the program and potential next steps, including the possibility of running another trial [32][34] - **Scleroderma Trial**: Ongoing trial for scleroderma-related ILD, with promising early results in skin symptom improvement [30][31] Additional Important Content - **Changing Treatment Practices**: Efzofitimod is influencing treatment patterns, with clinicians actively reducing steroid use based on trial data [27][28] - **Operational Readiness**: aTyr Pharma has demonstrated capability in enrolling and executing clinical trials, positioning itself well for future studies [42] This summary encapsulates the key points discussed during the conference call, highlighting aTyr Pharma's innovative approach to treating inflammation and fibrosis through efzofitimod and its implications for future clinical practice and regulatory discussions.

Core Insights - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][3] - The company will present at the Piper Sandler 37 Annual Healthcare Conference on December 2, 2025, in New York, NY [1][2] Company Overview - aTyr leverages evolutionary intelligence to translate tRNA synthetase biology into new therapies targeting fibrosis and inflammation [3] - The company's lead therapeutic candidate, efzofitimod, is an immunomodulator in clinical development for treating interstitial lung disease, which involves immune-mediated disorders causing lung inflammation and progressive fibrosis [3]

Efzofitimod for Interstitial Lung Disease (ILD) - Efzofitimod is a first-in-class biologic immunomodulator in Phase 3 development for ILD, addressing a significant unmet medical need[10] - aTyr is advancing Efzofitimod as the standard-of-care for ILD, which encompasses over 200 types of rare lung diseases[11, 13] - The company's current focus is estimated at a $2-5 billion global market opportunity[13] - Efzofitimod is positioned to be the first approved product for sarcoidosis in over 60 years[31] Clinical Development and Trial Design - Phase 3 catalyst for multi-billion dollar indication in Q3 2025[6] - The Phase 3 EFZO-FIT study in pulmonary sarcoidosis is fully enrolled with 268 patients, and topline data is expected in Q3 2025[50] - Interim data from the Phase 2 EFZO-CONNECT study in SSc-ILD is expected in Q2 2025[70] - The addressable population for Efzofitimod in sarcoidosis is estimated to be 50-75% of all sarcoidosis patients[28] Financial Position and Pipeline - The company had approximately $68.9 million in cash, restricted cash, cash equivalents, and investments as of Q3 2024, with an additional $19.4 million raised subsequently[70] - The company's cash runway extends through the filing of a Biologics License Agreement (BLA) for efzofitimod in pulmonary sarcoidosis[70]

Core Insights - aTyr Pharma is progressing with its clinical program for efzofitimod, a first-in-class biologic immunomodulator targeting pulmonary sarcoidosis, with topline data from the Phase 3 EFZO-FIT™ study expected in Q3 2025 [1][4][3] Company Updates - The first quarter of 2025 saw aTyr Pharma report a net loss of $14.88 million, compared to a loss of $15.49 million in the same period of 2024, with total revenues remaining at $0 [13] - Research and development expenses for Q1 2025 were $11.8 million, primarily for clinical trial costs related to the EFZO-FIT™ and EFZO-CONNECT™ studies [10][13] - The company appointed Dalia R. Rayes as Head of Commercial for the Global Efzofitimod Franchise, bringing over 25 years of experience in biotechnology and pharmaceutical commercial organizations [4] Clinical Trials - The Phase 3 EFZO-FIT™ study is a randomized, double-blind, placebo-controlled trial involving 268 patients across 85 centers in nine countries, focusing on steroid reduction as the primary endpoint [4][7] - The ongoing Phase 2 EFZO-CONNECT™ study aims to evaluate efzofitimod in patients with systemic sclerosis-related interstitial lung disease, with interim data expected in Q2 2025 [4][7] Financial Position - As of March 31, 2025, aTyr Pharma had cash and cash equivalents totaling $78.8 million, which is projected to fund operations for one year following the Phase 3 EFZO-FIT™ readout [10][15] - General and administrative expenses for Q1 2025 were reported at $4.0 million, slightly higher than the previous year's $3.5 million [10][13]

Core Viewpoint - aTyr Pharma has appointed Dalia R. Rayes as Head of Commercial for the Global Efzofitimod Franchise, aiming to advance the commercialization of efzofitimod, a potential first treatment for pulmonary sarcoidosis in over 70 years [1][2]. Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform, targeting therapies for fibrosis and inflammation [4]. - The lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), which includes immune-mediated disorders causing lung inflammation and fibrosis [4]. Appointment Details - Dalia R. Rayes brings over 25 years of experience in biotechnology and pharmaceuticals, having led product launches in rare diseases [1][2]. - Ms. Rayes previously served as Senior Vice President at ChemoCentryx, where she developed the commercial strategy for TAVNEOS® prior to its acquisition by Amgen [2]. - She has also held significant roles at Actelion Pharmaceuticals, contributing to the launch of products like VALCHLOR® and OPSUMIT® [2]. Compensation Package - As part of her appointment, Ms. Rayes was granted an option to purchase 225,000 shares of aTyr's common stock at an exercise price of $3.49 per share, with a vesting schedule over four years [3].

Financial Data and Key Metrics Changes - The company ended 2024 with $75.1 million in cash, restricted cash, cash equivalents, and investments [42] - Collaboration and license revenue related to the Kyorin agreement was $0.2 million for the year ended 2024 [43] - Research and development expenses were $54.4 million for the year ended 2024, primarily for clinical trial costs [43] - General and administrative expenses were $13.8 million for the year ended 2024 [43] - The company raised approximately $18.8 million in gross proceeds from its at-the-market offering program after the end of Q4 2024 [42] Business Line Data and Key Metrics Changes - The company completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, the largest interventional study ever conducted in this area [10][11] - The EFZO-FIT study enrolled 268 patients at 85 centers in 9 countries [12] - The company is also conducting the EFZO-CONNECT study for ILD-related systemic sclerosis, which is currently enrolling patients [28] Market Data and Key Metrics Changes - The company estimates a total global market opportunity for efzofitimod in ILD at $2 billion to $5 billion, with sarcoidosis representing a significant portion of that range [25] - A third-party claims analysis confirmed that the number of patients diagnosed with lung involvement is 30% higher than previously estimated, indicating a larger market opportunity [22] Company Strategy and Development Direction - The company aims to position efzofitimod as a potential frontline steroid-reducing agent in patients with moderate to severe sarcoidosis, addressing 50% to 75% of all sarcoidosis patients [24] - The company is preparing for commercial readiness and has appointed Eric Benevich to its Board of Directors to assist in this effort [26] - The company is exploring additional therapeutic areas for efzofitimod, including scleroderma and other fibrotic diseases, based on its unique mechanisms of action [39][106] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the favorable safety profile of efzofitimod and the potential for a significant market opportunity with little competition [47] - The company is optimistic about the upcoming Phase 3 EFZO-FIT readout and potential filing of a Biologics License Application for efzofitimod [44] - Management highlighted the importance of the recent publication in Science Translational Medicine, which validates the drug's mechanism of action [47] Other Important Information - The company has conducted four positive data and safety monitoring board reviews for the EFZO-FIT study, all of which have identified no safety concerns [14] - The company plans to present findings related to baseline demographics and disease characteristics at the upcoming American Thoracic Society Conference [15] Q&A Session Summary Question: Can you shed some light on how measuring the absolute change in steroid reduction impacts the trial? - Management explained that the new approach simplifies data analysis and maintains over 90% powering for the trial [54] Question: What is the percent of patients in the trial rolling over into the expanded access program? - Management noted that interest in the EAP is robust, but specific numbers are difficult to provide due to varying regulatory requirements across countries [56] Question: Was the market research around managing patients with steroid reduction related to the change in the statistical analysis plan? - Management clarified that the change was based on discussions with the FDA and aimed at simplifying the analysis [70] Question: What are the expected results from the interim analysis for the scleroderma program? - Management indicated that the focus will be on skin assessments, which are critical for understanding the drug's impact on quality of life [104] Question: How should we think about the durability of the drug impact with the new analysis approach? - Management emphasized that durability is important and will be assessed through various endpoints, including time to relapse [87]

Financial Data and Key Metrics Changes - The company ended 2024 with $75.1 million in cash, restricted cash, cash equivalents, and investments [31] - Research and development expenses were $54.4 million for the year, primarily for clinical trial costs and manufacturing [32] - General and administrative expenses totaled $13.8 million for the year [32] Business Line Data and Key Metrics Changes - Collaboration and license revenue related to the Kirin agreement was $200,000 for the year, with over $20 million received to date [31] - The company is eligible for up to $155 million in additional milestone payments from Kirin, primarily for regulatory and commercial milestones for sarcoidosis [31] Market Data and Key Metrics Changes - The company estimates a total global market opportunity for esofitimod in interstitial lung disease (ILD) at $2 billion to $5 billion, with sarcoidosis representing a significant portion of that range [20] - Recent claims analysis indicates that the number of patients diagnosed with lung involvement is 30% higher than previously estimated, with around 200,000 people affected in the U.S. [16][17] Company Strategy and Development Direction - The company aims to position esofitimod as a potential frontline steroid-reducing agent for patients with moderate to severe sarcoidosis, addressing 50% to 75% of all sarcoidosis patients [20] - The company is also exploring esofitimod for ILD related systemic sclerosis (scleroderma), with a Phase II study currently enrolling patients [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the favorable safety profile of esofitimod, bolstered by four positive Data and Safety Monitoring Board reviews [11] - The company anticipates significant market opportunities with little competition in the sarcoidosis space, supported by new claims data [34] Other Important Information - The company recently appointed Eric Benovich, a seasoned executive in launching high-value pharmaceuticals, to its Board of Directors [21] - A publication in the journal Science Translational Medicine validates the immune regulatory properties of esofitimod, enhancing its scientific rationale [28] Q&A Session Summary Question: Can you shed some light on how measuring the absolute change in steroid reduction impacts the trial? - Management explained that the new method simplifies data analysis and maintains over 90% powering for the trial [39][40] Question: What is the percent of patients in the trial rolling over into the expanded access program? - Management noted that interest in the expanded access program is robust, but specific numbers are difficult to provide due to varying regulatory requirements across countries [42][44] Question: What should investors look for in the baseline demographics from the study? - Management highlighted the importance of average prednisone dose and background immunomodulator use as key metrics to monitor [55] Question: How should we think about the durability of the drug impact? - Management indicated that durability is crucial and will be assessed through time to relapse and clinical worsening as tertiary endpoints [62] Question: What is the current manufacturing readiness for potential commercialization? - Management confirmed that significant investments have been made to ensure commercial readiness and drug supply for patients [86][88]

Core Insights - The independent data and safety monitoring board (DSMB) has recommended the continuation of the Phase 3 EFZO-FIT™ study of efzofitimod without any modifications, indicating no safety concerns [1][2] - The study aims to position efzofitimod as a potential chronic maintenance therapy for pulmonary sarcoidosis, with topline results expected in Q3 2025 [2] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][4] - The lead therapeutic candidate, efzofitimod, is being investigated for its efficacy and safety in treating pulmonary sarcoidosis and other interstitial lung diseases (ILD) [3][4] Study Details - The EFZO-FIT™ study is a global Phase 3 randomized, double-blind, placebo-controlled trial involving 268 subjects, assessing the efficacy of efzofitimod administered intravenously at doses of 3.0 mg/kg or 5.0 mg/kg [2][3] - The primary endpoint is steroid reduction, while secondary endpoints include lung function and sarcoidosis symptoms [2]